-
700 million cardiovascular injections
Time of Update: 2021-12-27
According to data from Meinenet, in 2020, the sales of nicorandil for terminal injection in China's public medical institutions exceeded the 700 million yuan mark, an increase of more than 50% year-on-year in the first half of this year, and the only manufacturer was Beijing Sihuan Kebao Pharmaceutical .
-
Accept this holiday gift
Time of Update: 2021-06-08
On May 31, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced the opening of the "Children's Drug Column" on June 1, and will centrally disclose policies, regulations, guidelines, and training materials related to children's drug use.
-
Rongchang Bioc-Met Targets ADC for the first time in China to be approved clinically
Time of Update: 2021-01-19
Insight data show that most of the c-MET targeted drugs currently under study in China are small molecule drugs, and only 4 antibody drugs are currently in clinical stage, namely, Xi'an Jansen's EGFR/c-Met dual anti-Amivantamab, AbbVie's ADC drug ABBV-399, Hengrui's ADC drug injection with SHR-A1403, and Upper Coast's EGFR/c-Met dual anti-EMB-01 injection.
